Finerenone cuts CV risk in patients with diabetes and kidney disease

The new agent reduces hospitalisation for heart failure and renal disease progression, research shows

AusDoc brings you the latest news from the European Society of Cardiology Congress 2021.

The first-in-class non-steroidal mineralocorticoid receptor antagonist finerenone improves cardiovascular outcomes in patients with type 2 diabetes and early-stage kidney disease, a major trial shows.

The multinational FIGARO-DKD trial, which included Australian patients, reduced the occurrence of its primary endpoint - cardiovascular death, non-fatal